Advertisement
Advertisement
May 22, 2026
Sentante Endovascular Robotic Platform Receives CE Mark Approval
KEY TAKEAWAYS
- Sentante robotic platform is approved in Europe to support endovascular procedures.
- Marketing of the device will begin in Europe with initial rollout and clinician training.
- Company recently unveiled its precision-controlled digital indeflator for endovascular procedures.
May 22, 2026—Sentante, a Lithuania-based medical technology company, announced that its flagship endovascular robotic platform has received CE Mark approval. The approval allows the company to begin marketing and selling the device across European markets.
The platform is designed to support endovascular procedures—including angioplasty and stent deployment—with enhanced precision and control, stated the company.
In its press release, Sentante advised that the approval marks its transition from research and development to commercialization. The company stated its next steps include an initial market rollout, clinician training, commercial expansion, and continued development of its product pipeline.
Additionally, Sentante noted that it recently unveiled a digital indeflator, which is a precision-controlled system intended to replace traditional manual indeflator devices used during endovascular procedures.
Advertisement
Advertisement
